<DOC>
	<DOCNO>NCT00785980</DOCNO>
	<brief_summary>Ciprofloxacin moderate inhibitor cytochrome P450 1A2 ( CYP1A2 ) , one enzymes responsible metabolism quinine . This study evaluate effect ciprofloxacin-related inhibition CYP1A2 pharmacokinetics quinine sulfate .</brief_summary>
	<brief_title>Drug - Drug Interaction Study Quinine Sulfate Ciprofloxacin</brief_title>
	<detailed_description>Ciprofloxacin moderate inhibitor cytochrome P450 1A2 ( CYP1A2 ) , one enzymes responsible metabolism quinine . This study evaluate effect ciprofloxacin-related inhibition CYP1A2 pharmacokinetics quinine sulfate . In morning study Day 1 fast least 10 hour , twenty-four healthy , non-smoking , non-obese , non-pregnant adult volunteer age 18 45 give one oral dose quinine sulfate ( 2 x 324 mg capsule ) . Fasting continue 4 hour dose . Blood sample draw participant dose 36 hour post-dose time sufficient adequately define pharmacokinetics quinine sulfate . A 7-day washout period complete first dose quinine sulfate Day 1 . Beginning 07:45 Day 8 continue Day 10 , subject return clinic non-confined dosing ciprofloxacin ( 1 x 500 mg tablet ) every 12 hour . Administered ciprofloxacin dos day fast state . At 07:45 Day 11 fast least 10 hour , study participant receive co-administered single oral dose quinine sulfate ( 2 x 324 mg capsule ) ciprofloxacin ( 1 x 500 mg tablet ) . A final dose ciprofloxacin ( 1 x 500 mg tablet ) administer 12 hour later . Blood sample draw participant dose 36 hour post-dose time sufficient adequately define pharmacokinetics quinine sulfate . Fasting continue 4 hour follow co-administered dose quinine sulfate ciprofloxacin . A goal study evaluate safety tolerability regimen healthy volunteer . Subjects monitor throughout participation study adverse reaction study drug and/or procedure . Seated blood pressure pulse measure pre-dose 1 , 2 3 hour post-dose Days 1 11 . An electrocardiogram ( ECG ) do pre-dose 1 , 2 4 hour post-dose Days 1 11 . All adverse event whether elicited query , spontaneously report , observe clinic staff evaluate Investigator report subject 's case report form .</detailed_description>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Quinine</mesh_term>
	<criteria>Healthy adult 1845 year age Nonsmoking Nonpregnant ( postmenopausal , surgically sterile use effective contraceptive measure ) Body mass index ( BMI ) 18 32 Medically healthy basis medical history physical examination Hemoglobin &gt; = 11.5 g/dL Completion screening process within 28 day prior dose Provision voluntary write informed consent Recent participation ( within 28 day ) research study Recent significant blood donation plasma donation Pregnant lactate Test positive screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) Recent ( 2year ) history evidence alcoholism drug abuse History presence significant cardiovascular , pulmonary , hepatic , gallbladder biliary tract , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease Subjects use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pglycoprotein ( Pgp ) within 28 day prior first dose throughout study Drug allergy mefloquine quinidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>quinine sulfate</keyword>
	<keyword>ciprofloxacin</keyword>
	<keyword>drug interaction</keyword>
	<keyword>cytochrome p450</keyword>
	<keyword>male</keyword>
	<keyword>female</keyword>
	<keyword>adult</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>